fulvestrant

Type: Keyphrase
Name: fulvestrant
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Pfizer : Announces Submission of Palbociclib New Drug Application to the FDA

By a News Reporter-Staff News Editor at Biotech Week -- Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, ... [Published 4 Traders - Aug 28 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Palbociclib Submitted to FDA for Breast Cancer Approval

the Cancer Therapy Advisor take:Pfizer has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for palbociclib for the treatment of estrogen receptor-positive and human epidermal growth factor 2-negative advanced breast cancer ... [Published Chemotherapy Advisor - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 1 reports

Pfizer Submits Palbociclib Marketing Application to the FDA

Pfizer Inc. ( PFE - Analyst Report ) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA. The company is looking to get the candidate approved in combination with Novartis’ ( NVS - Analyst ... [Published Zacks.com - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

Pfizer Announces Submission of Palbociclib New Drug Application To The FDA

Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the ... [Published Benzinga.com - Aug 18 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Modeling Luminal breast cancer heterogeneity: combination therapy to suppress a hormone ...

IntroductionMany Luminal breast cancers are heterogeneous, containing substantial numbers of estrogen (ER) and progesterone (PR) receptor-negative cells among the ER?+?PR?+?ones. One such subpopulation we call ?Luminobasal? is ER-, PR- and cytokeratin ... [Published 7thSpace - Aug 13 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Forum Post: RE: Fulvestrant

Hi Pat,I don't have any experience of Fulvestrant, you may get more response if you post it in the Breast Cancer group.I did find some information on the site about possible side effects etc. that may be useful to you. Here is the link:FulvestrantHope ... [Published Macmillan Cancer Support - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

AstraZeneca PLC : Second Quarter & Half Year Results 2014

AstraZeneca PLCSECOND Quarter AND HALF YEAR Results 2014London, 31 July 2014Revenue in the second quarter was $6,454 million, up 4%* - second consecutive quarter of revenue growth. Half year revenue up 3%, driven by the five growth platforms. Core EPS ... [Published Investegate - Jul 31 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Eli Lilly's (LLY) CEO John Lechleiter on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. Welcome to the Q 2014 earnings call. At this time, all participants are in a listen only mode. Later we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this conference ... [Published Seeking Alpha - Jul 25 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Mount Kisco Medical Group and Northern Westchester Hospital Now...

Cancer Treatment and Wellness Center is one of the first sites in the world to provide patients with access to leading edge breast cancer drug trial PALOMA-3. The Cancer Treatment and Wellness Center at Northern Westchester Hospital is now enrolling patients ... [Published PRWeb - Jun 24 2014]
First reported May 19 2014 - Updated May 19 2014 - 1 reports

Pfizer to submit palbociclib NDA with US FDA based on final results of PALOMA-1

Pfizer Inc. will submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human ... [Published PharmaBiz - May 19 2014]
First reported May 13 2014 - Updated May 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Revision: 12, Authorised

First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged PFS in patients with advanced breast cancer

Pfizer Inc. announced detailed results from the PALOMA-1 study, a randomized phase 2 study of palbociclib (PD-0332991) in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared ... [Published PharmaBiz - Apr 07 2014]

Quotes

"Today's submission marks an important milestone for Pfizer and palbociclib, and a potential advance for women with advanced breast cancer" said Garry Nicholson , President, Pfizer Oncology...
...measures and a reconciliation of Core to Reported financial measures Pascal Soriot, Chief Executive Officer, commenting on the results, said "We have made significant progress in the first half of the year, with visible momentum across our cardiovascular, diabetes and respiratory franchises as well as strong growth in the emerging markets. This has driven revenue growth for the second consecutive quarter and achieved a 13% increase in Core EPS in the quarter. The pace of execution of our strategy and the underlying performance of our teams give us confidence to raise 2014"
...Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. "We are proud to be at the forefront of research and development with respect to this promising new class of investigational anticancer agents and have initiated a broad clinical development programme for palbociclib that includes breast and non-breast cancers.”"

More Content

All (15) | News (14) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Pfizer : Announces Submission of Palbociclib Ne... [Published 4 Traders - Aug 28 2014]
Palbociclib Submitted to FDA for Breast Cancer ... [Published Chemotherapy Advisor - Aug 21 2014]
Pfizer Submits Palbociclib Marketing Applicatio... [Published Zacks.com - Aug 19 2014]
Pfizer Announces Submission of Palbociclib New ... [Published Benzinga.com - Aug 18 2014]
Pfizer Announces Submission of Palbociclib New ... [Published Wall Street Select - Aug 18 2014]
Modeling Luminal breast cancer heterogeneity: c... [Published 7thSpace - Aug 13 2014]
Forum Post: RE: Fulvestrant [Published Macmillan Cancer Support - Aug 04 2014]
AstraZeneca PLC : Second Quarter & Half Year Re... [Published Investegate - Jul 31 2014]
Eli Lilly's (LLY) CEO John Lechleiter on Q2 201... [Published Seeking Alpha - Jul 25 2014]
Mount Kisco Medical Group and Northern Westches... [Published PRWeb - Jun 24 2014]
Pfizer to submit palbociclib NDA with US FDA ba... [Published PharmaBiz - May 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer’s novel CDK 4/6 inhibitor palbociclib pl... [Published PharmaBiz - Apr 07 2014]
Fulvestrant 500 mg vs 250 mg in CONFIRM Trial [Published BioPortfolio - Feb 13 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.